A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Filip Jankú(The University of Texas MD Anderson Cancer Center), Alex A. Adjei(Cleveland Clinic), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Afshin Dowlati(University Hospitals of Cleveland), Vladimir Cmiljanović(PIQUR Therapeutics (Switzerland)), Grace M. Choong(Mayo Clinic in Florida), Sarah P. Blagden(Churchill Hospital), Andreas Wicki(University Hospital of Basel), Mateusz Opyrchal(Indiana University Health), Martin Förster, Nataša Cmiljanović(PIQUR Therapeutics (Switzerland)), Jun Yin(Mayo Clinic), Cinta Hierro(Vall d'Hebron Hospital Universitari), Hélène Müller(TU Dortmund University), Joel M. Reid(Children's Hospital of Philadelphia)
Cited by 13
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
|Annals of the American Thoracic Society|2018|723
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
|Journal of Clinical Oncology|1999|697